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Abstract
This commentary discusses pertinent issues from Hyosun Kim’s paper on online prescription drug promotion. 
The study is well-designed and the findings highlight some of the consequences of the Food and Drug 
Administration’s (FDA’s) decision to deregulate online advertising of prescription drugs. While Kim’s findings 
confirm some of the early concerns, they also provide a perspective of implementation challenges in the ever-
changing technological environment. 
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The main purpose of the study is to understand the Food and Drug Administration’s (FDA’s) concerns regarding online promotion of prescription drugs 
advertised directly to consumers. Hyosun Kim’s paper, 
“Trouble spots in online direct-to-consumer prescription 
drug promotion: a content analysis of FDA warning letters,”1 
analyzes warning letters to pharmaceutical firms over a 10-
year period. The study finds six categories of violations: risk 
information, efficacy information, indication information, 
product labeling, material information issues, and approval 
issues. The study concludes with the difficulties of presenting 
drug information in mass media in a fair and balanced way. 
The study is well-designed and the paper clearly written. While 
the findings are not new, the study sheds new light on the 
increasingly complex issues surrounding direct-to-consumer 
advertising (DTCA). Looking back to when the FDA loosened 
the restrictions more than 15 years ago, Kim’s findings offer an 
important contribution on the long term consequences of the 
decision and whether potential benefits outweigh the risks. 
In addition, the findings highlight the broader challenges of 
regulating the ever-changing industry.2 The prevailing state of 
the regulation is far from what was initially conceived and is 
fraught with unintended consequences. 
The findings raise important issues regarding the state of 
the regulation. According to the findings, 95% of alleged 
allegations were found in branded drug websites, online paid 
ads and online videos. This raises the question of whether 
the FDA is focusing specifically on these platforms and 
how it is aligning its enforcement strategies with the rapid 
transformation of social media.3 
There are a number of implications from the findings: 
insufficient risk information, limited advertising space to 
provide necessary information and little consumer protection 
from misleading information. While the study is aimed at 
diagnosing issues that pharmaceutical marketers should avoid 
in their online promotional material,1 these implications 
should be of concern to other stakeholders. 
Following the FDA’s decision in 1997, pharmaceutical 
companies were allowed to advertise prescription drugs over 
mass media. Studies, including the federal government’s own 
Government Accountability Office,4 have found inadequate 
review of pharmaceutical advertisements by the FDA and 
poor enforcement or remedial actions.5,6 On the other hand, 
some studies have argued that direct-to-consumer (DTC) 
is more honest and forthcoming than most other consumer 
advertising and has potential life-saving benefits if deployed 
appropriately.7 
Evidently, since the FDA let the genie out of the bottle, the 
prescription promotional industry has grown exponentially 
to a multibillion industry and will continue to thrive in the 
foreseeable future.2 Ultimately, Kim recommends industry 
guidance in addressing visibility and accessibility of 
information in the web environment to help pharmaceutical 
marketers meet the requirements for DTC promotion and to 
protect consumers from misleading drug information. The 
viability of these recommendations needs to be understood 
by looking at some of the following assumptions. 
The study and its conclusions appear to make some implicit 
assumptions. The first assumption is that pharmaceutical 
firms have a selfless motive and their interests are aligned 
with those of consumers and the FDA. While some interests 
are aligned, there is a world of conflict and motivation to 
act in ways that are at odds with each other. In addition, 
warning letters imply serious violations, and there is no way 
of knowing whether these were deliberate or honest mistakes. 
Kim’s study found that major violations were based on the 
lack of risk information and/or misrepresentation of efficacy 
information. The fact that some pharmaceutical firms did 
not include these essential attributes in a drug points to 
an underlying problem of self-interest-seeking behavior 
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and possibly deceptive marketing.8 Kim’s findings appear 
to highlight the conundrum of marketing efforts that are 
focused on increasing sales. Deception, whether calculated or 
unintended, that continues to prevail. 
The second implicit assumption is that the FDA has sufficient 
knowledge to identify potential violations. Due to asymmetric 
information, the FDA may not be in a position to know all 
the happenings in the industry and must rely, in part, on self-
disclosure by the pharmaceutical firms. Kim’s article alludes 
to the emergent nature of online advertising platforms and 
efforts by regulators to catch up. There is a bigger problem 
of information impactedness. The pharmaceutical firms 
have deeper knowledge on their prescription drugs than the 
FDA; in addition, the FDA lacks the necessary capacity and 
resources to fully process this information and have to rely 
on the pharmaceutical firms. In an ideal world, promotional 
packages would have to be pre-approved by the FDA in order 
to ensure full compliance with the rules. 
Consumers are also assumed to be “enlightened enough” 
to decipher information that is made available to them. 
The other issue raised by Kim regarding character space 
limitations is relevant here.1 Vulnerable consumers, including 
patients with chronic illnesses and despair due to illness, may 
minimize side effects and contraindications of drug options 
availed to them.9 
The findings shed light to institutional challenges surrounding 
violations that involve warning letters. Do letters of violation 
incentivize marketers to comply with the FDA’s regulations? 
While the specific nature of violations has not been 
documented, it would be assumed that these violations fall on 
a spectrum of gross to not-so-serious in terms of deleterious 
impact on patients. The question is whether the FDA has 
sufficient will to institute proportionate actions and remedial 
actions for affected consumers.
Over the decades the FDA has continued to provide a 
leadership role in regulating the pharmaceutical industry 
around the world. Since most pharmaceutical firms are global, 
there is increased pressure on other regulatory agencies 
to liberalize the online advertising space in Europe and 
beyond. This is against the backdrop of controversy regarding 
deregulation by FDA. Kim’s findings highlight the complexity 
of implementing such regulations without the necessary tools 
to do so.10 
The proliferation of and new prescription drug promotion 
online and specifically over social media will continue to 
exacerbate the hazards and unforeseen consequences in 
the foreseeable future. The competitive environment in the 
pharmaceutical industry has also gone through significant 
transformation and is increasingly competitive. More 
significant, in the absence of data-driven risks and benefits, 
regulatory actions will continue to be determined in the 
context of incomplete information, lobbying and politics. 
Kim’s findings begin to put some of the issues into perspective. 
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